Claims
- 1. A method for in vivo carcinoma targeting which comprises administering to an animal a pharmaceutically acceptable amount of a composition comprising an anti-TAG-72 mouse-human chimeric antibody produced by one of the cell lines CH44-1 (ATCC HB9884), CH44-2 (ATCC HB9880), CH44-4 (ATCC HB9877), CH88-1 (ATCC HB9882), CH88-2 (ATCC HB9881), CH88-3 (ATCC HB9876), CH88-4 (ATCC HB9874), CH84-1 (ATCC HB9883), CH84-2 (ATCC HB9879), CH84-3 (ATCC HB9878), or CH84-4 (ATCC HB9875), or an antibody fragment thereof, said antibody or fragment being conjugated to an imaging marker or therapeutic agent, in a pharmaceutically acceptable, non-toxic, sterile carrier, wherein said antibody is capable of binding to TAG-72 with an affinity at least 25% greater than that of B72.3, with the binding affinities of B72.3 and said antibody being measured by the same technique.
- 2. The method according to claim 1, wherein the imaging marker is selected from the group consisting of .sup.125 I, .sup.131 I, .sup.123 I, .sup.111 In, .sup.105 Rh, .sup.153 Sm, .sup.67 Cu, .sup.67 Ga, .sup.166 Ho, .sup.177 Lu, .sup.186 Re, .sup.188 Re, and .sup.99m Tc.
- 3. The method according to claim 1, wherein the therapeutic agent is selected from the group consisting of radionuclides, drugs, biological response modifiers, toxins, and other antibodies.
- 4. The method according to claim 3, wherein the radionuclide is selected from the group consisting of .sup.131 I, .sup.90 Y, .sup.105 Rh, .sup.47 Sc, .sup.67 Cu, .sup.212 Bi, .sup.211 At, .sup.67 Ga, 125I, .sup.186 Re, .sup.188 Re, .sup.177 Lu, .sup.99m Tc, .sup.153 Sm, .sup.123 I and .sup.111 In.
- 5. The method according to claim 3, wherein the drug or biological response modifier is selected from the group consisting of methotrexate, adriamycin, and interferon.
- 6. The method according to claim 1 wherein said method further comprises a step of localizing said antibody or fragment upon one or more tumors, by detecting the imaging marker or therapeutic agent to which such antibody or fragment is conjugated, said step being performed after the step of administering the composition to an animal.
- 7. The method according to claim 6 wherein said method further comprises a step of excising the tumor(s) upon which said antibody or fragment has been localized, whereby said method is utilized for intraoperative therapy.
- 8. The method according to claim 6, wherein the imaging marker is selected from the group consisting of .sup.125 I, .sup.131 I, .sup.123 I, .sup.111 In, .sup.105 Rh, .sup.153 Sm, .sup.67 Cu, .sup.67 Ga, .sup.166 Ho, .sup.177 Lu, .sup.186 Re, .sup.188 Re, and .sup.99m Tc.
- 9. The method according to claim 6 wherein the therapeutic agent is a radionuclide.
- 10. The method according to claim 9 wherein said radionuclide is selected from the group consisting of .sup.131 I, .sup.90 Y, .sup.105 Rh, .sup.47 Sc, .sup.67 Cu, .sup.212 Bi, .sup.211 At, .sup.67 Ga, 125I, .sup.186 Re, .sup.188 Re, .sup.177 Lu, .sup.99m Tc, .sup.153 Sm, .sup.123 I, and .sup.111 In.
- 11. The method according to claim 7, wherein the imaging marker is selected from the group consisting of .sup.125 I, .sup.131 I, .sup.123 I, .sup.111 In, .sup.105 Rh, .sup.153 Sm, .sup.67 Cu, .sup.67 Ga, .sup.166 Ho, .sup.177 Lu, .sup.186 Re, .sup.188 Re, and .sup.99m Tc.
- 12. The method according to claim 7 wherein the therapeutic agent is a radionuclide.
- 13. The method according to claim 12 wherein said radionuclide is selected from the group consisting of .sup.131 I, .sup.90 Y, .sup.105 Rh, .sup.47 Sc, .sup.67 Cu, .sup.212 Bi, .sup.211 At, .sup.67 Ga, 125I, .sup.186 Re, .sup.188 Re, .sup.177 Lu, .sup.99m Tc, .sup.153 Sm, .sup.123 I, and .sup.111 In.
CROSS REFERENCE
The present application is divisional application from application U.S. Ser. No. 08/040,687, filed Mar. 31, 1993, which is a continuation-in-part of U.S. Ser. No. 07/424,362, filed Oct. 19, 1989 (now abandoned), which is a continuation-in-part of U.S. Ser. No. 07/261,942, filed Oct. 24, 1988 (now abandoned), which is a continuation of U.S. Ser. No. 07/259,943, filed Oct. 19, 1988 (now abandoned).
US Referenced Citations (6)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 239 400 |
Sep 1987 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
040687 |
Mar 1993 |
|
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
424362 |
Oct 1989 |
|
Parent |
261942 |
Oct 1988 |
|
Parent |
259943 |
Oct 1988 |
|